Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus FLUOCINONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus FLUOCINONIDE.
CAPEX vs FLUOCINONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Fluocinonide is a potent corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced prostaglandin and leukotriene synthesis. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply a thin film to affected area 1-3 times daily. Limitation of use: Should not exceed 60 g per week in adults.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Clinical Note
moderateFluocinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Gatifloxacin."
Clinical Note
moderateFluocinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Rosoxacin."
Clinical Note
moderateFluocinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 1.3-2.4 hours in plasma. Clinically, due to high tissue binding and slow release from skin, the pharmacodynamic half-life for topical effect may extend to 12-24 hours.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily hepatic metabolism; inactive metabolites excreted renally and fecally. Renal elimination accounts for approximately 60-70% of total clearance, fecal elimination ~30-40%. Less than 1% excreted unchanged in urine.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
Fluocinonide + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Trovafloxacin."